Navigation Links
Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide
Date:6/19/2008

AMSTERDAM, The Netherlands, June 19 /PRNewswire/ -- Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. R.M. Bergkamp, on behalf of the Honourable Mrs. Maria van der Hoeven, Minster of Economic Affairs for The Netherlands.

"Agendia has a distinguished history of providing exceptional high quality diagnostic testing services that provide valuable information for cancer patients and the physicians who treat them," said Dr. Bernhard Sixt, Agendia's president & chief executive officer (CEO). "The expanded capacity of our laboratories at our new location will allow us to meet the growing worldwide demand for our clinical services as we expand into major markets, enhancing the company's ability to serve the healthcare community."

The new facilities offer 13,000 square feet of laboratory and office space that will support the company's molecular diagnostic cancer testing services and research activities.

"Additionally, this move proves our ability to replicate our FDA-cleared and CLIA-certified laboratory in a new location in just 4 months," said Dr. Jan Groen, vice president and chief operating officer (COO) at Agendia. "The increased laboratory space will also allow the company to expand our research and product development capabilities to enhance commercialization of emerging diagnostic discoveries in cancer."

Currently, Agendia offers three test services through its expanded laboratories, including MammaPrint(R), based on the Amsterdam 70-gene profile that indicates risk of recurrence for breast cancer tumors and the first in vitro diagnostic multi index variant assay (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA), and CupPrint(R), which identifies the origin of metastases with un
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Time Magazine Names Agendia Test a Best Invention of 2007
2. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
3. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
4. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
5. Rohm and Haas Expands in India
6. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
7. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
8. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
9. Specialty Blades, Inc. Expands Management Team With New VP Engineering
10. CRH Medical expands Las Vegas operations
11. US Med-Equip Expands Corporate Support Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
(Date:9/2/2015)... ... September 02, 2015 , ... Specifically, ... the news recently following a decision by the Centers for Medicare & Medicaid ... to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an ... of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone ... usability. A leader in health technology, RxNT was one of the first to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
(Date:9/2/2015)... ... 2015 , ... A UPMC and University of Pittsburgh Schools ... a premier center for treatment of and research into hereditary hemorrhagic telangiectasia (HHT), ... , Cure HHT, previously known as The HHT Foundation International, has designated ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... BEIJING, June 26 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin ... China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"),has obtained ... that aid in manufacturing blood dialysis. , ... for patents for its core,technology with the State Intellectual ...
... HOUSTON, June 26 The Breast Center at Houston Northwest ... the United States -- and one in Texas -- to ... by the National Quality Measures for Breast Centers (NQMBC) Program(TM). ... measure performance of interdisciplinary breast care nationwide. The designation is ...
... ... in Omaha list for the second straight year. The list is sponsored by the Greater Omaha ... an Omaha business. , ... June 26, 2009 -- Healthcare staffing company Medical Solutions has landed on the ...
... DC (26 June, 2009) Combating high blood pressure ... enjoyed reductions in cardiovascular disease over recent decades, Latin ... published in the journal Therapeutic Advances in Cardiovascular ... the increase in many Latin American countries, a situation ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... the Food and Drug Administration, today arrived and seized ... also included ingredients held at these same facilities. The ... in May 2009, found unresolved violations of cGMP requirements ...
... Texas, June 25 Torchmark Corporation (NYSE: TMK ... $300 million in aggregate principal amount of 9.25% Senior Notes ... to close on June 30, 2009, subject to the satisfaction ... offering will be used for the repayment of the $99.45 ...
Cached Medicine News:Health News:RainEarth Obtains Patent Approvals for Its Core Technology 2Health News:RainEarth Obtains Patent Approvals for Its Core Technology 3Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 2Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4Health News:Latin America must cut blood pressure to thrive 2Health News:Latin America must cut blood pressure to thrive 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action 2Health News:Torchmark Prices Senior Notes Offering 2
(Date:9/2/2015)... Calif. , Sept. 2, 2015  ArmaGen, ... developing revolutionary therapies to treat severe neurological disorders, ... dosed in its multi-center Phase 1/2a clinical trial ... I (MPS I). AGT-181 is ... treatment of MPS I. The most severe form ...
(Date:9/2/2015)... , Sept. 2, 2015  Boca Raton ... FACS, has begun performing ultra-minimally invasive left atrial ... on anticoagulants such as Coumadin, Xarelto or Effient. ... at the Hospital, is one of a select ... involves making two microscopic incisions in order to ...
(Date:9/2/2015)... Elekta, a global cancer management company, ... 10, 6:30-8:30 p.m., at Elekta,s North American headquarters in ... " will feature Professional BMX athlete, Josh Perry , ... with Leksell Gamma Knife®, Elekta,s radiosurgery system for treating brain ... be diagnosed in Georgia in 2015 ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3
... , SEATTLE , Sept. 21 ... that it will re-focus its resources on the approval of OPAXIO(TM) ... The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III ... versus an untreated control arm. To date, 600 patients have been ...
... , , THOUSAND ... ) today announced detailed results from a Phase 3 trial ... an intravenous infusion in the treatment of bone metastases in ... and prostate cancer) or multiple myeloma. These results were ...
Cached Medicine Technology:Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis 2Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis 3Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis 4Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 2Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 3Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 4Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 5Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 6Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 7Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 8Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 9
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Medicine Products: